Finanzen von Nautilus Biotechnology Inc (NAUT)NAUTNautilus Biotechnology Inc

Evaluating the bottom line, Nautilus Biotechnology, Inc. maintains a gross margin of 92.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8296.32%, while the net margin is -7615.26%. These profitability ratios, combined with a Return on Equity (ROE) of -36.21%, provide a clear picture of how effectively NAUT converts its operational activities into shareholder value.

In the context of the broader market, NAUT competes directly with industry leaders such as SEER and ONCY. With a market capitalization of $123.74M, it holds a leading position in the sector. When comparing efficiency, NAUT's gross margin of 92.11% stands against SEER's 98.71% and ONCY's N/A. Such benchmarking helps identify whether Nautilus Biotechnology, Inc. is trading at a premium or discount relative to its financial performance.

Nautilus has generated its first revenue of $0.19 million in Q2 2026, but it has also reported significant net losses, with a net loss of $14.47 million this quarter, indicating ongoing financial challenges. The gross margin is notably high at 92.11%, but the company has not yet established a consistent revenue stream.